"Suddenly one day, the doctor told me that the cancer has metastasized." At the end of 2015, Ms. Li diagnosed a high-density adenocarcinoma of the rectum. After 3 months of routine chemotherapy after surgery, liver metastases were found at the age of 46 years.
According to the National Cancer Registry and the Cancer Prevention and Control Office's analysis of 17 cancer registries and 139,000 cases nationwide, the five-year survival rate of cancer patients in China is 30.9%, only half of the US (66%). .
Ms. Li continued to receive standard cancer therapy, but she thought that it was not necessarily the most effective means, so she did another unusual thing: let a domestic research institute cultivate its tumor tissue and use it in experiments. The tumor cell population produced during the proliferation of the chamber has tested dozens of drugs, and hopes to find out the most effective group of drugs for Ms. Li. "As a patient, I don't have time to accept these therapies one by one, and my body can't bear it," Ms. Li explained.
This idea seems strange, but the truth is very simple: to understand the enemy, we must first cultivate the enemy. Right now, researchers around the world are trying to cultivate real tumors in vitro using tissue engineering. Researchers from the Georgetown University Medical Center in the United States have developed and tested a revolutionary laboratory technology called "conditional reprogramming," which allows unrestricted culture of normal cells in the laboratory. And diseased cells.
However, this technique has a weakness: that is, the CR system simultaneously amplifies the normal and tumor cells of the patient, which makes it impossible to distinguish which cell subgroup from which the drug sensitive signal is derived, thereby severely limiting its clinical application. Beijing-based Percans Oncology has been developing clinical susceptibility testing technology based on CR principle since three years ago. It has successfully broken through the selective CR amplification technology of tumor cells and became the first domestic to utilize this technology. A company that provides patients with personalized drug susceptibility testing services.
Zhikangbo and Peking Union Medical College Hospital launched a formal clinical study for patients with advanced intestinal cancer in February 2017, and it is expected to quickly find effective personalized treatment for every patient with intestinal cancer. Ms. Li’s original help was also Zhikang’s drug, and she quickly found the right drug recommendation in the standard treatment plan through the drug sensitivity test. Dr. Chen Yiyou, the president of the company, pointed out: "The individual tumor differentiation is obvious, and different patients have different responses to the same treatment plan. There is an urgent need for a new auxiliary means to help doctors to guide medication, from diagnostics and Therapeutic (diagnositics) The relative independence of treatment), the integrated transformation of Theranostics diagnosis and treatment."
Dr. Chen Yiyou participated in the 1st National Cancer Center International Forum on Colorectal Cancer
Dr. Chen pointed out that it is the public opinion in the industry. According to the tissue of the disease and the images under the microscope, cancer can be divided into hundreds of different types; in fact, they should be of the order of millions. Cancer often has hundreds of variations and more types of epigenetic changes. Each tumor is unique and constantly changing and evolving.
We're professional Monopolar Forceps manufacturers and suppliers in China, specialized in providing high quality medical instruments with reasonable price. We warmly welcome you to buy or wholesale bulk forceps for sale here and get quotation from our factory.
Monopolar Forceps,Laparoscopic Forceps,Laparoscopic Grasping Forceps,Laparoscopic Dissecting Forceps
Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com